| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
DENV RdRp (RNA-dependent RNA polymerase). NITD-2 prevents the DENV RdRp protein from causing RNA elongation, thereby blocking viral RNA amplification. Resistance to NITD-2 is linked to mutations in the viral RdRp that alter its affinity for the drug, such as the S759N substitution.
|
|---|---|
| ln Vitro |
NITD-2 prevents the creation of new RNA [1]. The lack of antiviral action shown by NITD-2 in cell culture was caused by inadequate cell penetration[1].
In vitro, NITD-2 inhibits DENV RdRp-mediated RNA elongation in enzymatic assays. It is widely used to characterize replication-blocking responses due to its strong inhibition of viral RNA amplification pathways. Detailed IC50 values for viral replication in cell culture are available from specialized databases. |
| ln Vivo |
In vivo activity data for NITD-2 is not extensively detailed in the literature. As a DENV polymerase inhibitor, it is expected to reduce viral load and improve survival in animal models of dengue virus infection. Its poor cell membrane permeability may limit its in vivo efficacy.
|
| Enzyme Assay |
In vitro enzyme assays use recombinant DENV RdRp protein, a primer-template RNA substrate, and NTPs. The incorporation of radioactive or fluorescently labeled nucleotides is measured. The compound is incubated with the enzyme and substrates, and the inhibition of RNA elongation is quantified. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In vitro antiviral activity is assessed in DENV-infected cell lines (e.g., Vero, Huh-7 cells). Cells are treated with NITD-2 and viral RNA levels are measured by qRT-PCR. Viral titers are determined by plaque assay. Cytotoxicity is evaluated using standard cell viability assays (e.g., MTT).
|
| Animal Protocol |
In vivo efficacy studies are typically performed in mouse models of DENV infection using immunocompromised mice (e.g., AG129 mice). NITD-2 is administered via intraperitoneal or oral routes. Viral loads in blood and tissues are quantified by qRT-PCR. Survival rates and clinical scores are monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NITD-2 include poor cell membrane permeability, which may limit its oral bioavailability and tissue distribution. It has a molecular weight of 433.48 and is soluble in DMSO. It is recommended to store at -20°C and protect from light.
|
| Toxicity/Toxicokinetics |
Detailed toxicological profiles of NITD-2 are not extensively reported. As a research compound, it is expected to have a manageable safety profile at the concentrations used in antiviral assays. Cytotoxicity is assessed in parallel with antiviral activity in cell-based assays to determine the selectivity index.
|
| References | |
| Additional Infomation |
NITD-2 is a research compound targeting dengue virus polymerase. It is used in antiviral drug discovery efforts and to study flavivirus replication. It is not approved for clinical use. Its molecular formula is C23H19N3O4S and its molecular weight is 433.48.
|
| Molecular Formula |
C23H19N3O4S
|
|---|---|
| Molecular Weight |
433.4797
|
| Exact Mass |
433.11
|
| Elemental Analysis |
C, 63.73; H, 4.42; N, 9.69; O, 14.76; S, 7.40
|
| CAS # |
1197896-79-9
|
| PubChem CID |
44607341
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
704
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CN2C=C(C=N2)C3=CC(=CC=C3)S(=O)(=O)NC4=CC=CC=C4C(=O)O
|
| InChi Key |
PHQOBFYGHBBCBV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H19N3O4S/c27-23(28)21-11-4-5-12-22(21)25-31(29,30)20-10-6-9-18(13-20)19-14-24-26(16-19)15-17-7-2-1-3-8-17/h1-14,16,25H,15H2,(H,27,28)
|
| Chemical Name |
2-[[3-(1-benzylpyrazol-4-yl)phenyl]sulfonylamino]benzoic acid
|
| Synonyms |
NITD2; NITD 2; NITD-2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~230.7 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3069 mL | 11.5346 mL | 23.0691 mL | |
| 5 mM | 0.4614 mL | 2.3069 mL | 4.6138 mL | |
| 10 mM | 0.2307 mL | 1.1535 mL | 2.3069 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
